Moeller & Co. CapitalMoeller & Co. Capital AG
MandateInvestment Pillars

A focused mandate.
Three pillars.

We do not chase themes. We commit to verticals where our network gives us a structural edge, and we revisit that commitment annually. The current pillars have been refined over two decades of operating, advising, and investing across European capital markets.
Life Science
IPillar I · Life Science

Science Meets Strategy

Clinical-stage biotech and medtech with defensible IP, validated regulatory pathways, and operators who have done it before. We back companies whose science is past the speculative phase and whose value inflection lies in execution, not invention.

How we evaluate

  • Defensible IP and freedom-to-operate
  • Regulatory pathway already mapped (FDA / EMA)
  • Operators with prior approval or exit
  • Plausible strategic acquirer set

Active value creation

We assemble disease-area advisory groups around each portfolio company. Former CEOs of listed orthobiology and medtech firms sit on our diligence calls. We do not pretend to know more than the science — we know who does, and we make sure they are in the room.

Anonymized vignette

A Lund-based orthobiology company developing synthetic bone for spinal fusion. Founding team from a previously-acquired listed peer. FDA Breakthrough Device Designation secured prior to our engagement.

See current focus — Moroxite
German Real Estate
IIPillar II · German Real Estate

Stability in Europe's Engine

Undervalued residential and commercial assets in Munich, Hamburg, Berlin, Frankfurt, and the Rhine corridor. Long hold periods. Patient capital. Yield supported by fundamentals, not financial engineering.

How we evaluate

  • Sub-replacement-cost entry basis
  • Demographic tailwind in micro-location
  • Conservative leverage; no refi risk in horizon
  • Operator with on-the-ground execution capacity

Active value creation

We co-invest alongside specialist German operators with twenty-year track records. Asset management, capex planning, and exit timing are run by partners who have transacted through three real-estate cycles in Germany.

Anonymized vignette

A residential portfolio in Munich-Süd, acquired below replacement cost from a distressed family-office vendor. Held with a ten-year horizon; cash-yielding from year one.

Disruptive Technologies
IIIPillar III · Disruptive Technologies

Backing the Builders

B2B SaaS, applied AI, and green-tech with revenue traction, defensible architecture, and founder–market fit. We invest at the inflection where product has been validated and the question is no longer whether — but how fast.

How we evaluate

  • Demonstrated revenue with high gross margin
  • Architectural moat — not just feature parity
  • Founder with credible domain expertise
  • Capital efficiency in prior rounds

Active value creation

Former founder–CEOs from comparable categories sit on our advisory calls. We help pressure-test go-to-market hypotheses, board composition, and the financing path to the next inflection — not the next round.

Anonymized vignette

A European B2B SaaS company in supply-chain optimization. Founders from a previously-acquired listed peer. Backed at Series A inflection alongside a strategic European LP.